South Western Sydney Clinical School

Entyvio lengthen dose-interval study: Lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease

Chan W; Lynch N; Bampton P; Chang J; Chung A; Florin T; Hetzel DJ; Jakobovits S; Moore G; Pavli P, 2018, 'Entyvio lengthen dose-interval study: Lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease', European Journal of Gastroenterology and Hepatology, vol. 30, pp. 735 - 740, 10.1097/MEG.0000000000001150

Back to Top